Home > Publications database > MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance. > print

001     306549
005     20260220154842.0
024 7 _ |a 10.1038/s41586-025-09916-w
|2 doi
024 7 _ |a pmid:41286180
|2 pmid
024 7 _ |a 0028-0836
|2 ISSN
024 7 _ |a 1476-4687
|2 ISSN
037 _ _ |a DKFZ-2025-02614
041 _ _ |a English
082 _ _ |a 500
100 1 _ |a White, Mark
|0 0000-0002-6309-3254
|b 0
245 _ _ |a MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance.
260 _ _ |a London [u.a.]
|c 2026
|b Nature Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1771598861_3240617
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2026 Feb;650(8102):748-758
520 _ _ |a The colorectal epithelium is rapidly renewing, with remarkable capacity to regenerate following injury. In colorectal cancer (CRC), this regenerative capacity can be co-opted to drive epithelial plasticity. While oncogenic MAPK signalling in CRC is common, with frequent mutations of both KRAS (40-50%) and BRAF (10%)1, inhibition of this pathway typically drives resistance clinically. Given the development of KRAS inhibitors, and licensing of BRAF inhibitor combinations2-4, we have interrogated key mechanisms of resistance to these agents in advanced preclinical CRC models. We show that oncogenic MAPK signalling induces epithelial state changes in vivo, driving adoption of a regenerative/revival stem like population, while inhibition leads to rapid transcriptional remodeling of both Kras- and Braf-mutant tumours, favoring a Wnt-associated, canonical stem phenotype. This drives acute therapeutic resistance in Kras- and delayed resistance in Braf-driven models. Importantly, where plasticity is restrained, such as in early metastatic disease, or through targeting ligand-dependent Wnt-pathway Rnf43 mutations, marked therapeutic responses are observed. This explains the super response to BRAF+EGFR targeted therapies previously observed in a BRAF/RNF43 co-mutant patient population, highlighting the criticality of cellular plasticity in therapeutic response. Together, our data provides clear insight into the mechanisms underpinning resistance to MAPK targeted therapies in CRC. Moreover, strategies that aim to corral stem cell fate, restrict epithelial plasticity or intervene when tumours lack heterogeneity may improve therapeutic efficacy of these agents.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Mills, Megan L
|0 0009-0000-0922-7912
|b 1
700 1 _ |a Millett, Laura M
|0 0009-0000-7596-4275
|b 2
700 1 _ |a Gilroy, Kathryn
|0 0000-0003-4607-194X
|b 3
700 1 _ |a Hong, Yourae
|0 0000-0001-6683-433X
|b 4
700 1 _ |a Zeiger, Lucas B
|0 0000-0002-8712-3112
|b 5
700 1 _ |a Simpson, Rosalin J
|0 0009-0001-8571-7275
|b 6
700 1 _ |a Corry, Shania M
|b 7
700 1 _ |a Ligeza, Amelia
|0 0009-0006-9075-3138
|b 8
700 1 _ |a Lannagan, Tamsin R M
|0 0000-0002-8206-8898
|b 9
700 1 _ |a Susanti, Susanti
|0 0000-0001-9704-5157
|b 10
700 1 _ |a Ridgway, Rachel A
|0 0000-0003-0198-8244
|b 11
700 1 _ |a Yazgili, Ayse S
|0 0000-0001-8485-9653
|b 12
700 1 _ |a Grzesiak, Lucile
|0 0000-0002-7351-2045
|b 13
700 1 _ |a Amirkhah, Raheleh
|0 0000-0003-3494-271X
|b 14
700 1 _ |a Ford, Catriona A
|0 0000-0003-3991-6369
|b 15
700 1 _ |a Vlahov, Nikola
|0 0009-0002-8649-6109
|b 16
700 1 _ |a Tovell, Hannah
|0 0000-0002-2473-7256
|b 17
700 1 _ |a Officer-Jones, Leah
|0 0000-0002-3690-2386
|b 18
700 1 _ |a Ficken, Catherine
|0 0000-0003-4764-210X
|b 19
700 1 _ |a Pennie, Rachel
|0 0009-0001-4796-7388
|b 20
700 1 _ |a Najumudeen, Arafath K
|0 0000-0002-3764-5721
|b 21
700 1 _ |a Raven, Alexander
|0 0000-0003-4409-9543
|b 22
700 1 _ |a Nasreddin, Nadia
|0 0000-0002-3025-6213
|b 23
700 1 _ |a Chauhan, Ekansh
|0 0000-0002-1096-0625
|b 24
700 1 _ |a Papanastasiou, Andrew S
|0 0000-0002-8888-0633
|b 25
700 1 _ |a Nixon, Colin
|0 0000-0002-8085-2160
|b 26
700 1 _ |a Morrison, Vivienne
|0 0009-0009-1022-8969
|b 27
700 1 _ |a Jackstadt, Rene-Filip
|0 P:(DE-He78)5da14633266cbfff7746cf529c110673
|b 28
|u dkfz
700 1 _ |a Graham, Janet S
|0 0000-0002-2048-2698
|b 29
700 1 _ |a Miller, Crispin J
|0 0000-0003-4341-1283
|b 30
700 1 _ |a Ross, Sarah J
|0 0000-0001-8759-1728
|b 31
700 1 _ |a Barry, Simon T
|0 0000-0002-8511-0588
|b 32
700 1 _ |a Pavet, Valeria
|0 0000-0002-4472-6503
|b 33
700 1 _ |a Wilson, Richard H
|0 0000-0001-8018-7730
|b 34
700 1 _ |a Le Quesne, John
|0 0000-0003-3552-7446
|b 35
700 1 _ |a Dunne, Philip D
|0 0000-0001-9160-283X
|b 36
700 1 _ |a Tejpar, Sabine
|0 0000-0003-3281-8643
|b 37
700 1 _ |a Leedham, Simon
|0 0000-0003-1476-6982
|b 38
700 1 _ |a Campbell, Andrew D
|0 0000-0003-3930-1276
|b 39
700 1 _ |a Sansom, Owen J
|0 0000-0001-9540-3010
|b 40
773 _ _ |a 10.1038/s41586-025-09916-w
|0 PERI:(DE-600)1413423-8
|n 8102
|p 748-758
|t Nature
|v 650
|y 2026
|x 0028-0836
909 C O |p VDB
|o oai:inrepo02.dkfz.de:306549
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 28
|6 P:(DE-He78)5da14633266cbfff7746cf529c110673
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2025
915 _ _ |a DEAL Nature
|0 StatID:(DE-HGF)3003
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1060
|2 StatID
|b Current Contents - Agriculture, Biology and Environmental Sciences
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1200
|2 StatID
|b Chemical Reactions
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1210
|2 StatID
|b Index Chemicus
|d 2025-01-06
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NATURE : 2022
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-06
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-06
915 _ _ |a IF >= 60
|0 StatID:(DE-HGF)9960
|2 StatID
|b NATURE : 2022
|d 2025-01-06
920 1 _ |0 I:(DE-He78)A013-20160331
|k A013
|l NWG Tumorprogression und Metastasierung
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A013-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21